Ipca Laboratories, Aurobindo Pharma, Glenmark Share Price Rally As Nifty Pharma Hits 52-Week High

Pharmaceutical stocks traded higher on Wednesday even as the broader market remained weak. The Nifty Pharma index rose about 1% during intraday trade on the National Stock Exchange of India, touching a 52-week high of 23,540.90.

The index crossed its previous high of 23,492.55, which was recorded on January 7, 2026. Around mid-afternoon trading, the pharma index was still up about 0.74%, while the broader Nifty 50 index had declined by nearly 1.5%.

Over the past 1 month, the pharma index has gained 4.5%, while the benchmark Nifty 50 has fallen 7.8%, highlighting the sector’s outperformance.

Pharma Stocks Lead The Rally

Several pharmaceutical stocks moved higher during the session. Shares of Ipca Laboratories, Aurobindo Pharma, Glenmark Pharmaceuticals, Ajanta Pharma, Biocon, Lupin, Laurus Labs, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Divi's Laboratories rose between 1% and 4%.

Meanwhile, Ajanta Pharma, Aurobindo Pharma, Glenmark Pharmaceuticals, and JB Chemicals & Pharmaceuticals touched their 52-week highs during the session.

Rising Raw Material Costs May Push Drug Prices Higher

One reason behind the strong performance of pharma stocks is the possibility of higher medicine prices in India. The cost of key raw materials, known as Active Pharmaceutical Ingredients (APIs), has reportedly increased by nearly 30% in recent weeks.

Shipping disruptions linked to tensions around Iran have caused shortages of vessels, slowing the movement of raw materials from China, which is the largest supplier of pharmaceutical ingredients to India.

Growth In India’s API Market

India’s pharmaceutical ingredient exports have grown strongly. API exports reached about ₹41,500 crore in FY25, exceeding imports of ₹39,215 crore.

Over the past few years, the government has taken several steps to boost domestic manufacturing of APIs. This growth will be supported by government policies, rising domestic demand, and increasing exports to global markets.

Read More:YES Bank Share Price in Focus; Appoints Vinay Muralidhar Tonse as MD and CEO! 

Shift Towards Complex APIs

Pharmaceutical companies are gradually moving from producing basic APIs to high-potency and complex APIs. This shift can help companies improve profit margins, reduce price competition, and retain customers.

However, many projects related to complex API production are still under development and may take 2-4 years to reach full commercial production.

Despite progress, India still relies heavily on China for key starting materials used in drug manufacturing.

Conclusion

Pharma stocks are outperforming the broader market as investors look for defensive sectors during uncertain times. Rising raw material costs, possible drug price increases, and long-term growth in India’s API industry are supporting the rally in pharmaceutical companies.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.